Vor Biopharma (VOR) Operating Income (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Operating Income data on file, last reported at -$35.2 million in Q1 2026.

• On a quarterly basis, Operating Income fell 5.61% year-over-year to -$35.2 million in Q1 2026; TTM through Mar 2026 was -$373.5 million, a 205.78% decrease from a year earlier, with the FY2025 full-year figure at -$371.6 million, down 206.67% from the prior year.
• Operating Income for Q1 2026 stood at -$35.2 million, up from -$36.0 million in the prior quarter.
• Over the last five years, Operating Income for VOR reached as high as -$21.8 million in Q2 2022 and fell as low as -$274.3 million in Q2 2025.
• Historically, Operating Income has averaged -$44.0 million across 5 years, with a median of -$30.4 million in 2023.
• Across the five-year window, Operating Income rose 19.26% in 2024 and tumbled 844.67% in 2025, its largest moves.
• Year by year, Operating Income stood at -$24.7 million in 2022, then dropped by 13.75% to -$28.1 million in 2023, then declined by 11.33% to -$31.3 million in 2024, then slipped by 14.85% to -$36.0 million in 2025, then rose by 2.22% to -$35.2 million in 2026.
• Per Business Quant data, the three most recent Operating Income figures were -$35.2 million in Q1 2026, -$36.0 million in Q4 2025, and -$28.1 million in Q3 2025.